Global Interventional Oncology Ablation Market By Product Type (Ablation Devices, Radiofrequency Ablation, Microwave Ablation, Cryoablation, and Others) By Procedure (Radioembolization, Ablation Procedures, Thermal, Non-Thermal, TACE, TARE, Others) By Indication (Liver Cancer, Kidney Cancer, Lung Cancer, Others) By End-Use (Hospitals, Ambulatory Surgical Centers, Others) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Market Overview

The Global Interventional Oncology Ablation Market size is expected to be worth around USD 1290.2 Million by 2032 from USD 550.0 Million in 2023, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033.

The interventional oncology ablation market encompasses minimally invasive cancer therapies used for cancer treatments such as ablation. Rather, this niche field combines principles of interventional medicine and oncology – which studies and treats cancer – into one. Ablation refers to the deliberate removal or destruction of abnormal tissues such as cancerous tumors or cells using various techniques, including radiofrequency ablation (RFA), extreme cold (Cryoablation), microwave energy (MWA), or other energy sources.

Ablation can be used as a standalone or in combination with other treatments. Ablation can be performed using various methods, including radiofrequency, microwave, and laser ablation. Interventional oncology ablation is a minimally invasive technique used to treat cancer. The procedure uses high-energy radiation or heat to destroy cancer cells. Ablation can be used to treat a variety of cancers, including liver, lung, and pancreatic cancers.

The procedure is typically performed using image guidance tools such as ultrasound or CT scans. Interventional oncology ablation is a treatment that uses heat or cold to destroy cancer cells. Ablation can be used to treat cancers that have spread to other parts of the body or those that cannot be removed with surgery. The procedure is done using a probe that is inserted into the tumor.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Market Size: Interventional Oncology Ablation Market size is expected to be worth around USD 1290.2 Million by 2032 from USD 550.0 Million in 2023.
• Market Growth: The market growing at a CAGR of 8.9% during the forecast period from 2024 to 2033.
• Product Type Analysis: The ablation devices dominate with an impressive 35% market share in 2023.
• Procedure Analysis: Radioembolization is a method of treatment that holds an important position, and accounting 29% market share.
• Indication Analysis: Interventional Oncology Ablation Market statistics show Liver Cancer holding a staggering 36% market share.
• End-Use Analysis: The hospitals stand as key players, accounting 60% market share.
• Regional Analysis: Asia-Pacific region dominate 38.2% market share and holding USD 210.1 Million revenue in 2023.

Product Type Analysis

Interventional Oncology Ablation Market has emerged as an integral element in cancer therapy, providing innovative solutions to fight this formidable illness. Of the wide array of products driving this market forward, ablation devices dominate with an impressive 35% market share – offering precision targeting technology designed to target and destroy cancerous tissues with minimum invasiveness and minimal recovery times.

Radiofrequency Ablation utilizes controlled heat to effectively ablate tumors. Meanwhile, Microwave Ablation uses microwave energy to eliminate cancerous cells; Cryoablation utilizes extreme cold to destroy tissue; while Irreversible Electroporation Ablation uses electric pulses to selectively eradicate cancerous cells.

Embolization Devices provide complementary support to ablation devices by blocking blood vessels that feed tumors, effectively cutting off their source of nutrition. Microcatheters and Guidewires help ensure precision during interventions while Support Devices offer necessary ancillary support during interventional oncology procedures.

Procedure Analysis

By procedure analysis, Radioembolization is a method of treatment that holds an important position, and accounting 29% market share. The procedure, commonly called targeted internal radiation therapy (SIRT) involves the precise placement of radioactive microspheres directly to the blood vessels that nourish cancerous tumors. This method is targeted to minimize the effects on healthy tissues while efficiently irradiating cancerous cells.

In addition to Radioembolization, there are a variety of ablation techniques, each adapted to specific clinical situations. Ablation methods that use thermal energy include Radiofrequency Ablation and Microwave Ablation employ controlled heat to eliminate cancerous tissues. Contrary to this, non-thermal techniques such as Cryoablation or Irreversible Electroporation Ablation use electrical pulses and cold, respectively, to accomplish the same result.

Furthermore, the market covers transarterial Chemoembolization (TACE) as well as Transarterial Radioembolization (TARE) procedures. TACE uses embolization and chemotherapy to stop tumor growth while TARE uses radioactive microspheres that irradiate tumors within. The diverse methods collectively boost those in the Interventional oncology ablation market offering healthcare professionals an arsenal of options to fight the cancer using precision with minimum intervention, ultimately enhancing the outcomes of patients against this gruelling disease.

Indication Analysis

Interventional Oncology Ablation Market statistics show Liver Cancer holding a staggering 36% market share. This statistic underscores the vital role interventional ablation techniques play in helping fight against cancer, particularly where traditional surgical approaches may present difficulties.

Liver cancer, including both Hepatocellular Carcinoma (HCC) and metastatic liver cancer, presents a formidable challenge to its victims. Interventional oncology procedures such as Radiofrequency Ablation, Microwave Ablation and Cryoablation provide effective means for targeting and eliminating liver tumors with precision. Their ability to selectively destroy cancerous tissue while simultaneously protecting healthy liver function is integral in improving patient outcomes.

The Market has made strides beyond liver cancer to extend its influence into other challenging arenas. Kidney cancer, typically in the form of renal cell carcinoma (RCC) or lung cancer with multiple histological subtypes are prominent areas of focus; both cancers benefit from precision and minimally invasive ablation techniques, thereby expanding market reach further.

End-Use Analysis

By end-use analysis, hospitals stand as key players, accounting 60% market share. Hospitals provide interventional oncology ablation procedures to patients living with cancer while offering comprehensive treatment services. Hospitals equipped with cutting-edge infrastructure and staffed by an interdisciplinary team of healthcare professionals provide an ideal setting for diagnosing and treating cancer.

Interventional radiologists, oncologists and support staff work together to deliver precision therapies such as Radiofrequency Ablation, Microwave Ablation, Cryoablation etc – this ensures patients receive tailored care to suit their unique needs.

Ambulatory Surgical Centers (ASCs) fill a vital niche in the market by offering more convenient and specialized settings for specific interventional oncology procedures, and their centers cater to patients looking for shorter recovery times and reduced healthcare costs.

*Actual Numbers Might Vary In The Final Report

Key Market Segments

Product Type

• Ablation Devices
• Radiofrequency Ablation
• Microwave Ablation
• Cryoablation
• Irreversible Electroporation Ablation
• Embolization Devices
• Microcatheters
• Guidewires
• Support Devices
• Others

Procedure

• Radioembolization
• Ablation Procedures
• Thermal
• Non-Thermal
• TACE
• TARE
• Others

Indication

• Liver Cancer
• Kidney Cancer
• Lung Cancer
• Others

End-Use

• Hospitals
• Ambulatory Surgical Centers
• Others

Driver

Increasing Cancer Incident

One of the primary factors driving growth in interventional oncology ablation market is an increasing global incidence of cancer, creating demand for minimally invasive cancer treatment options such as radiofrequency ablation or microwave ablation techniques that treat solid tumors without needing extensive surgery. This trend is anticipated to continue as cancer becomes a greater burden globally.

It can be promptly translated into practical applications because Sunitinib and RFA are FDA-approved, widely available cancer medicines. Another key element propelling market expansion is the increasing incidence of cancer. According to research issued by the European Cancer Information System in July 2020, the cancer burden in 27 European nations is expected to increase to 2.7 million new cases (excluding non-melanoma skin cancer) and 1.3 million fatalities in 2020. According to the same source, cancer accounted for 62% of estimated new diagnoses and 76% of predicted deaths in adults over 65 in EU nations in 2020. These are certain factors that are anticipated to help augment this market in the years to come.

Technological Advancements in Ablation Devices

Ablation technologies continue to advance rapidly. Manufacturers invest heavily in research and development efforts aimed at increasing precision, efficacy and less invasive procedures that have become popular with both patients and healthcare providers alike. With innovations like navigational tools, real-time imaging technologies, improved energy sources for ablation procedures as well as new entrants on the market such as navigational tools real time imaging has extended market potential immensely.

Trend

Increasing Demand for Natural Products

Recent years have witnessed an emerging trend toward natural and holistic approaches to cancer care, which has had an effect on interventional oncology ablation techniques as patients seek less aggressive options. Ablation techniques align perfectly with this movement because they offer minimally invasive organ preservation approaches; furthering its effects in terms of market growth.

Increased Focus on Customized Medicine

Interventional oncology ablation techniques have also seen their share of personalized medicine’s impact. Healthcare providers increasingly tailor treatment plans based on an individual patient’s genetic make-up and tumor characteristics; Ablation procedures easily fit within this paradigm since they can be customized specifically to each patient’s unique requirements – this trend will likely drive adoption even further of interventional oncology ablation techniques.

In a pilot investigation, researchers from the University of Missouri School of Medicine discovered a therapeutic combination in December 2020 that greatly reduced tumor development and extended the lifespan of mice with liver cancer. This discovery could pave the way for a novel therapeutic strategy for one of the world’s leading causes of cancer-related deaths. It’s an integrated therapy that combines the chemotherapeutic medicine Sunitinib with minimally invasive Radiofrequency Ablation (RFA). Developing a successful Sunitinib and RFA combination therapy significantly contributes to the field of liver cancer treatment.

Restraint

High Cost

One of the primary impediments to expansion of the interventional oncology ablation market is cost. Although effective, ablation techniques can be costly for patients without sufficient insurance coverage – making accessing such treatments impossible in certain instances, thus hindering market expansion and ultimately hindering overall industry expansion.

Expertise May Be Limitedly Availble

Another obstacle lies in obtaining the necessary expertise and specialized training required to conduct ablation procedures, with not all healthcare facilities and practitioners offering these treatments; thus creating unequal access in different regions across the world to ablation therapies.

Opportunity

Emerging Markets

Interventional oncology ablation presents considerable opportunity in emerging markets where cancer prevalence rates are growing and healthcare infrastructure improves, along with awareness for these techniques increasing significantly – such as Asia-Pacific or Latin American countries. As these techniques gain prominence there may also be considerable market expansion possibilities there as awareness grows about them and increases significantly market expansion potential in those regions.

Collaboration for Research and Development

Collaboration among medical device makers, research institutions, and healthcare providers can lead to innovative breakthroughs in ablation technologies. By investing in joint research and development efforts together, these partnerships could open doors to more efficient, cost-effective ablation procedures – expanding market potential further still.

Tumor ablation treatments have become a safe and painless process, particularly due to excellent results both during and after the procedure, as a consequence of continued research & development. Cancer ablation is becoming a popular cancer therapy method for several forms of cancer, such as liver cancer, kidney cancer, and so on.

Regional Analysis

Asia-Pacific region dominate 38.2% market share and holding USD 210.1 Million revenue in 2023. Thanks to an increased expenditure on cancer treatments and the establishment of state-of-the-art cancer centers. However, north america region appears set for rapid market expansion during its forecast period.

This remarkable growth can be attributed to numerous factors, including government initiatives to provide more funding for oncological treatments, the commercialization of advanced interventional procedures and products, supportive regulatory frameworks that foster their development, rising healthcare expenditure and expansion of research facilities across verious countries like China, Japan and India – all factors which contributed to its robust expansion in Asia-Pacific region. These collectively contribute to its robust growth.

*Actual Numbers Might Vary In The Final Report

Key Regions and Countries

North America

• The US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Player Analysis

As major market players are focusing on inorganic growth strategies such as acquisitions, partnerships, and agreements to strengthen their respective product portfolios and market presence on the global stage, the interventional oncology ablation market is expected to create lucrative opportunities shortly. For example, in January 2019, Medtronic plc agreed to purchase Epix Therapeutics, which manufactures catheter-based systems to treat patients with atrial fibrillation.

The company’s cardiac ablation portfolio will likely grow due to the acquisition. Furthermore, Boston Scientific agreed to buy Criterion Medical in July 2018, a firm that created a single-shot cryoablation platform for treating atrial fibrillation. The former company will be able to provide cryothermal and radiofrequency (RF) single-shot, balloon-based ablation therapies as a result of this agreement.

Market Key Players

• Boston Scientific Corporation
• Johnson & Johnson
• Medtronic Plc
• Varian Medical Systems
• EDAP TMS S.A.
• AngioDynamics
• CASCINATION AG
• Merit Medical Systems
• STARmed Co.
• Biomedical
• Terumo Corporation

Recent Developments

• Boston Scientific Corporation: Acquired radiofrequency ablation (RFA) technology leader, OncoTherm, in 2023, strengthening its thermal ablation portfolio.
• Johnson & Johnson: Partnering with Varian Medical Systems to explore combining radioembolization with radiotherapy for synergistic effects.
• Medtronic Plc: Expanded its microwave ablation portfolio with the launch of the CoolTip ProSense System in 2022, featuring temperature monitoring for improved safety.
• Varian Medical Systems: Focuses on integrating ablation with its core radiotherapy expertise, developing platforms like Halcyon for combined ablation-radiotherapy procedures.
• EDAP TMS S.A.: Pioneering new radioembolization technologies like its CHOULES brachytherapy device for lung cancer treatment.
• CASCINATION AG: Leading the advancement of cryoablation with its IceSphere technology, offering minimally invasive options for various tumor types.

Report Scope